Splenic marginal zone lymphoma

Blood

Volumn 101, Issue 7, 2003, Pages 2464-2472

  Franco, Vito ^a   Florena, Ada Maria ^b   Iannitto, Emilio ^b  

^a Ist Anat e Istol Patol Policlin   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; CELL ADHESION MOLECULE; CLADRIBINE; CYCLOPHOSPHAMIDE; HERMES ANTIGEN; IBRITUMOMAB TIUXETAN; L SELECTIN; PENTOSTATIN; PURINE DERIVATIVE; RIBAVIRIN; TOSITUMOMAB;

AGGRESSION; ANTIBODY LABELING; B CELL LYMPHOMA; BILIARY CIRRHOSIS; BLAST TRANSFORMATION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL STRUCTURE; CHROMOSOME 7Q; CHROMOSOME MUTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFECTION; LABORATORY TEST; LYMPHOCYTOSIS; MANTLE CELL LYMPHOMA; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RADIATION DOSE; REVIEW; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; TUMOR GROWTH; VIRUS INFECTION; WORLD HEALTH ORGANIZATION; ANIMAL; CHROMOSOME ANALYSIS; GENETICS; NONHODGKIN LYMPHOMA; PATHOLOGY; SPLEEN TUMOR;

ANIMALS; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, LOW-GRADE; SPLENIC NEOPLASMS;

EID: 0038107404     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2216     Document Type: Review

References (144)

1. Isaacson PG, Piris MA, Catovski D, et al. Splenic marginal zone lymphoma. In Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumors of Haematopoietic and Lymphoid tissues. WHO Classification of Tumors. Lyon, France: IARC Press; 2001:135-137.
2. Pileri SA, Ascani S, Sabattini E, et al. The pathologist's view point, part I: indolent lymphomas. Haematologica. 2000;85:1291-1307.
3. Schmid C, Kirkham N, Diss T, Isaacson PG. Splenic marginal zone cell lymphoma. Am J Surg Pathol. 1992;16:455-466.
4. Melo JV, Robinson DS, Gregory C, Catovsky D. Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia. 1987;1:294-298.
5. Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994;84:3828-3834.
6. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol. 1999;36:148-154.
7. Franco V, Florena AM, Campesi G. Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma. Histopathology. 1996;29:571-575.
8. Labouyrie E, Marit G, Vial J, et al. Intrasinusoida bone marrow involvement by splenic lymphoma with villous lymphocytes: a helpful immunohistologic feature. Mod Pathol. 1997;10:1015-1020.
9. Morrison AM, Jager U, Chott A, Schebesta M, Haas OA, Busslinger M. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood. 1998;92:3865-3878.
10. O'Reilly RA. Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients. West J Med. 1998;169:88-97.
11. Zucca E, Bertoni F, Roggero E, Cavalli F. Management of rare forms of lymphoma. Curr Opin Oncol. 1998;10:377-384.
12. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795.
13. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950-1956.
14. Arber DA, Rappaport H, Weiss LM. Non-Hodgkin's lymphoproliferative disorders involving the spleen. Mod Pathol. 1997;10:18-32.
15. Coad JE, Matutes E, Catovsky D. Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature. Leuk Lymphoma. 1993;10:245-264.
16. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731-736.
17. Hammer RD, Glick AD, Greer JP, Collins RD, Cousar JB. Splenic marginal zone lymphoma. A distinct B-cell neoplasm. Am J Surg Pathol. 1996 20:613-626.
18. de Figueiredo M, Lima M, Macedo G, Ribeiro P. Association of splenic lymphoma with villous lymphocytes and primary biliary cirrhosis in a man. Sangre (Barc). 1996;41:262-263.
19. Takai K, Sanada M, Shibuya H. Primary splenic lymphoma complicated by malignant rheumatoid arthritis and bladder cancer. Rinsho Ketsueki. 1993;34:79-83.
20. Murakami H, Irisawa H, Saitoh T, et al. Immunological abnormarities in splenic marginal zone cell lymphoma. Am J Hematol. 1997;56:173-178.
21. Van Huyen JP, Molina T, Delmer A, et al. Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol. 2000;24:1581-1592.
22. Bonichon N, Lifermann F, Fossats A, Canteloup B, Dauzan Y. Autoimmune hemolytic anemia disclosing splenic lymphoma with villous lymphocyte [letter]. Presse Med. 1997;26:270.
23. Gale R, Smith OP, Wood M, Mehta AB. Splenic lymphoma with villous lymphocytes complicated by autoimmune haemolytic anaemia [letter]. Lancet. 1992;340:1106.
24. Bowen AL, Matutes E, Catovski D. Splenic lymphoma with villous lymphocytes. Haematologica. 1999;84(suppl 10):90-92.
25. Zeidman A, Fradin Z, Barac Y, Bendayan D, Mittelman M, Orlin J. Splenic lymphoma presenting as warm autoimmune hemolytic anemia associated with pure red cell aplasia. Vox Sang. 2000;78:126-129.
26. Farrell AM, Stern SC, El-Ghariani K, et al. Splenic lymphoma with villous lymphocytes presenting as leucocytoclastic vasculitis. Clin Exp Dermatol. 1999;24:19-22.
27. Chacón JI, Mollejo M, Muñoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648-1654.
28. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3:41-47.
29. Lioret E, Mollejo M, Mateo MS, et al. Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant? Hum Pathol. 1999;30:1153-1160.
30. Cualing H, Steele P, Zellner D. Blastic transformation of splenic marginal zone B-cell lymphoma. Arch Pathol Lab Med. 2000;124:748-752.
31. Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268-1276.
32. Dierlamm J, Stefanova M, Wlodarska I, et al. Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma: an interphase fluorescence in situ hybridization study. Cancer Genet Cytogenet. 2000;120:1-5.
33. Pawade J, Wilkins BS, Wright DH. Low-grade B-cell lymphomas of the splenic marginal zone: a clinicopathological and immunohistochemical study of 14 cases. Histopathology. 1995;27:129-137.
34. Mollejo M, Menarguez J, Lloret E, et al. Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. Am J Surg Pathol. 1995;19:1146-1157.
35. Wu CD, Jackson CL, Medeiros LJ. Splenic marginal zone cell lymphoma. An immunophenotypic and molecular study of five cases. Am J Clin Pathol. 1996;105:277-285.
36. Mollejo M, Algara P, Mateo MS, et al. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology. 2002;40:22-30.
37. Kent SA, Variakoijs D, Peterson LC. Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol. 2002;117:698-708.
38. Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91:294-301.
39. Mollejo M, Lloret E, Menarguez J, Piris MA, Isaacson PG. Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features. Am J Surg Pathol. 1997;21:772-780.
40. Campo E, Miquel R, Krenacs L, Sorbara L, Raffeld M, Jaffe ES. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol. 1999;23:59-68.
41. Rosso R, Castello A, Colosini G, Astori C, Lazzarino M, Magrini U. Splenic marginal zone cell lymphoma involving liver and bone marrow. Report of a case with protracted follow-up, showing progressive disappearance of the lymphoma after splenectomy. Haematologica. 1996;81:44-46.
42. Mollejo M, Algara P, Mateo MS et al. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology. 2002;40:22-30.
43. Orero MT, Miguel-Sosa A, Matutes E, et al. A soft tissue extranodal mass as an initial manifestation of splenic lymphoma with circulating villous lymphocytes [letter]. Br J Haematol. 1998;103:1213-1214.
44. Yamazaki K, Shimizu S, Negami T, et al. Leukemic meningitis in a patient with splenic lymphoma with villous lymphocytes (SLVL). Meningitis as a possible initial manifestation of SLVL. Cancer. 1994;73:61-65.
45. Gotlib V, Singareddy S, Gergis U, et al. Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2002;43:1337-1340.
46. Rosso R, Neiman RS, Paulli M, et al. Splenic marginal zone cell lymphoma: report of an indolent variant without massive splenomegaly presumably representing an early phase of the disease. Hum Pathol. 1995;26:39-46.
47. Lai R, Weiss LM, Chang KL, Arber DA. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43 follicular lymphomas. Am J Clin Pathol. 1999;111:488-494.
48. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood. 1996;87:299-307.
49. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852.
50. Salomon-Nguyen F, Valensi F, Troussard X, Flandrin G. The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders. Leuk Res. 1996;20:909-913.
51. Miranda RN, Cousar JB, Hammer RD, Collins RD, Vnencak-Jones CL. Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Hum Pathol. 1999;30:306-312.
52. Savilo E, Campo E, Mollejo M, et al. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol. 1998;11:601-606.
53. Swerdlow SH, Zukerberg LR, Yang WI, Harris NL, Williams ME. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements. Am J Surg Pathol. 1996;20:627-640.
54. Hoyer JD, Li CY, Yam LT, Hanson CA, Kurtin PJ. Immunohistochemical demonstration of acid phosphatase isoenzyme 5 (tartrate-resistant) in paraffin sections of hairy cell leukemia and other hematologic disorders. Am J Clin Pathol. 1997;108:308-315.
55. Chilosi M, Chiarle R, Lestani M, et al. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. Br J Haematol. 2000;111:263-271.
56. Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998;153:175-182.
57. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000;95:627-632.
58. Falini B, Tiacci E, Hatzivassiliou G, et al. IRTA1: a new molecule associated with normal and neoplastic marginal zone cells [abstract]. J Clin Pathol 2002;55(suppl 1):A31-32.
59. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol. 1998;11:457-463.
60. + B-cell phenotype. Intern Med. 1993;32:472-475.
61. Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 2000;89:445-452.
62. Camacho FI, Garcia JF, Sanchez-Verde L, et al. Unique phenotypic profile of monocytoid B cells: differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma. Am J Pathol. 2001;158:1363-1369.
63. Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG. Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum Pathol. 1998;29:585-593.
64. H gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood. 2002;100:2659-2661.
65. Dierlamm J, Pittaluga S, Stul M, et al. BCL6 gene rearrangements also occur in marginal zone B-cell lymphoma. Br J Haematol. 1997;98:719-725.
66. Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am J Clin Pathol. 1999;112:101-107.
67. Mateo MS, Mollejo M, Villuendas R, et al. Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5′ non-coding region of the bcl-6 gene. Leukemia. 2001;15:628-634.
68. Cuneo A, Bardi A, Wlodarska I, et al. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma. Leukemia. 2001;15:1262-1267.
69. Takashima T, Itoh M, Ueda Y, et al. Detection of 14q32.33 translocation and t(11;14) in interphase nuclei of chronic B-cell leukemia/lymphomas by in situ hybridization. Int J Cancer. 1997;72:31-38.
70. Sole F, Espinet B, Salido M, et al. Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes [letter]. Br J Haematol. 2000;110:241-243.
71. Sonoki T, Harder L, Horsman DE, et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood. 2001;98:2837-2844.
72. Garcia-Marco JA, Nouel A, Navarro B, et al. Molecular cytogenetic analysis in splenic lymphoma with villous lymphocytes: frequent allelic imbalance of the RB1 gene but not the D13S25 locus on chromosome 13q14. Cancer Res. 1998;58:1736-1740.
73. Oscier DG, Gardiner A, Mould S. Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders. Cancer Genet Cytogenet. 1996;92:24-27.
74. Wong KF, Chu YC, Hui PK. Splenic lymphoma with villous lymphocytes showing del(7) and inv(10). Cancer Genet Cytogenet. 1998;102:145-147.
75. Fujita M, Uno H, Hino N, Nakagawa H, Nagaoka K, Sasaki N. Splenic lymphoma with villous lymphocytes expressing chromosomal abnormalities [abstract]. Rinsho Ketsueki. 1999;40:330-335.
76. Sole F, Woessner S, Perez-Losada A, et al. Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders. Cancer Genet Cytogenet. 1997;93:160-166.
77. Mateo M, Mollejo M, Villuendas R, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol. 1999;154:1583-1589.
78. Corcoran MM, Mould SJ, Orchard JA, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271-6277.
79. Sole F, Salido M, Espinet B, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 2001;86:71-77.
80. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99:1299-1304.
81. Dierlamm J, Wlodarska I, Michaux L, et al. Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol. 2000;18:1-13.
82. Dierlamm J, Baens M, Stefanova-Ouzounova M, et al. Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes. Blood. 2000;96:2215-2218.
83. de Wolf-Peeters C, Pittaluga S, Dierlamm J, Wlodarska I, Van Den Berghe H. Marginal zone B-cell lymphomas including mucosa-associated lymphoid tissue type lymphoma (MALT), monocytoid B-cell lymphoma and splenic marginal zone cell lymphoma and their relation to the reactive marginal zone. Leuk Lymphoma. 1997;26:467-478.
84. Rosenwald A, Ott G, Stilgenbauer S, et al. Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas. Am J Pathol. 1999;155:1817-1821.
85. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000;156:1183-1188.
86. Maes B, Baens M, Marynen P, de Wolf-Peeters C. The product of the t(11;18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type. Ann Oncol. 2000;11:521-526.
87. Mateo MS, Mollejo M, Villuendas R, et al. Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas. Mol Pathol. 1998;51:262-267.
88. Ott MM, Rosenwald A, Katzenberger T, et al. Marginal zone B-cell lymphomas (MZBL) arising at different sites represent different biological entities. Genes Chromosomes Cancer. 2000;28:380-386.
89. Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood. 1995;85:2000-2004.
90. Dierlamm J, Michaux L, Wlodarska I, et al. Trisomy 3 in marginal zone B-cell lymphoma: a study based on cytogenetic analysis and fluorescence in situ hybridization. Br J Haematol. 1996;93:242-249.
91. Gruszka-Westwood AM, Matutes E, Coignet LJ, Wotherspoon A, Catovsky D. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol. 1999;104:600-604.
92. Brynes RK, Almaguer PD, Leathery KE, et al. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol. 1996;9:995-1000.
93. Batanian JR, Dunphy CH, Richart JM, Petruska PJ, Perkins SL. Simultaneous presence of t(2; 8)(p12;q24) and t(14;18)(q32;q21) in a B-cell lymphoproliferative disorder with features suggestive of an aggressive variant of splenic marginal-zone lymphoma. Cancer Genet Cytogenet. 2000;120:136-140.
94. Cuneo A, Bigoni R, Roberti MG, et al. Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases. Haematologica. 2001;86:64-70.
95. Hernandez JM, Garcia JL, Gutierrez NC, et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol. 2001;158:1843-1850.
96. Albertoni M, Daub DM, Arden KC, Viars CS, Powell C, Van Meir EG. Genetic instability leads to loss of both p53 alleles in human glioblastoma. Oncogene. 1998;16:321-326.
97. Bea S, Lopez-Guillermo A, Ribas M, et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol. 2002;161:957-968.
98. Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood. 2001;97:3552-3558.
99. Baldini L, Guffanti A, Cro L, et al. Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations. Br J Haematol. 1997;99:375-378.
100. Yuille MR, Condie A, Stone EM, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer. 2001;30:336-341.
101. Lombes A, Bories D, Girodon E, et al. The first pathogenic mitochondrial methionine tRNA point mutation is discovered in splenic lymphoma. Hum Mutat. 1998;11:S175-183.
102. Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161:81-88.
103. Hori M, Xiang S, Qi CF, et al. Non-Hodgkin lymphomas of mice. Blood Cells Mol Dis. 2001;27:217-222.
104. Fredrickson TN, Lennert K, Chattopadhyay SK, Morse HC 3rd, Hartley JW. Splenic marginal zone lymphomas of mice. Am J Pathol. 1999;154:805-812.
105. Tang JC, Ho FC, Chan AC, Chow EY, Srivastava G. Progression of spontaneous lymphomas in SJL mice: monitoring in vivo clonal evolution with molecular markers in sequential splenic samples. Lab Invest. 1998;78:1459-1466.
106. Hough MR, Reis MD, Singaraja R, et al. A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice. Proc Natl Acad Sci U S A. 1998;95:13853-13858.
107. Hartley JW, Chattopadhyay SK, Lander MR, et al. Accelerated appearance of multiple B cell lymphoma types in NFS/N mice congenic for ecotropic murine leukemia viruses. Lab Invest. 2000;80:159-169.
108. Ward JM, Tadesse-Heath L, Perkins SN, Chattopadhyay SK, Hursting SD, Morse HC 3rd. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab Invest. 1999;79:3-14.
109. Morse HC III, Anver MR, Fredrickson N, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100:246-258.
110. Murakami Y, Hotel H, Tsumura H, et al. A case of primary splenic malignant lymphoma and review of 98 cases reported in Japan [abstract]. J Jpn Soc Clin Surg. 1988;49:716-719.
111. Kumagawa M, Suzumiya J, Ohshima K, Kanda M, Tamura K, Kikuchi M. Splenic lymphoproliferative disorders in human T lymphotropic virus type-I endemic area of Japan: clinicopathological, immunohistochemical and genetic analysis of 27 cases. Leuk Lymphoma. 2001;41:593-605.
112. Satoh T, Yamada T, Nakano S, et al. The relationship between primary splenic malignant lymphoma and chronic liver disease associated with hepatitis C virus infection. Cancer. 1997;80:1981-1988.
113. Moccia F, Tognoni E, Boccaccio P. The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection. Ann Ital Med Int. 1999;14:288-293.
114. Luppi M, Ferrari MG, Bonaccorsi G, et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia. 1996;10:351-355.
115. Silvestri F, Barillari G, Fanin R, et al. Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas. Haematologica. 1997;82:314-317.
116. Marasca R, Vaccari P, Luppi M, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol. 2001;159:253-261.
117. Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002;26:630-636.
118. Bates I, Bedu-Addo G, Jarrett RF, et al. B-lymphotropic viruses in a novel tropical splenic lymphoma. Br J Haematol. 2001;112:161-166.
119. Bates I, Bedu-Addo G, Rutherford TR, Bevan DH. Circulating villous lymphocytes - a link between hyperreactive malarial splenomegaly and splenic lymphoma. Trans R Soc Trop Med Hyg. 1997;91:171-174.
120. Wallace S, Bedu-Addo G, Rutherford TR, Bates I. Serological similarities between hyperreactive malarial splenomegaly and splenic lymphoma in west Africa. Trans R Soc Trop Med Hyg. 1998;92:463-467.
121. Jimmy EO, Bedu-Addo G, Bates I, Bevan D, Rutherford TR. Immunoglobulin gene polymerase chain reaction to distinguish hyperreactive malarial splenomegaly from "African" chronic lymphocytic leukaemia and splenic lymphoma. Trans R Soc Trop Med Hyg. 1996;90:37-39.
122. Zhu D, Thompsett AR, Bedu-Addo G, Stevenson FK, Bates I. VH gene sequences from a novel tropical splenic lymphoma reveal a naive B cell as the cell of origin. Br J Haematol. 1999;107:114-120.
123. Steiniger B, Barth P, Hellinger A. The perifollicular and marginal zones of the human splenic white pulp. Am J Pathol 2001;159:501-512.
124. Kraal G, Schornagel K, Streeter PR, et al. Expression of the mucosal vascular addressin, MAdCAM-1, on sinus lining cells of the spleen. Am J Pathol. 1995;147:763-771.
125. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97-110.
126. Munro JM, Briscoe DM, Tedder TF. Differential regulation of leukocyte L-selectin (CD62L) expression in normal lymphoid and inflamed extra-lymphoid tissues. J Clin Pathol. 1996:49:721-727.
127. + progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol. 1995;23:1535-1542.
128. Papayannopoulou T, Craddock C. Homing and trafficking of hemopoietic progenitor cells. Acta Haematol. 1997;97:97-104.
129. Voermans C, van Hennick PB, van der Schoot CE. Homing of human stem and progenitor cells: new insights, new challenges? J Hematother Stem Cell Res. 2001;10:725-738.
130. Frenette PS, Subbarao S, Mazo IB, et al. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci U S A. 1998;95:14423-14428.
131. Vincent AM, Burthem J, Brew R, Cawley JC. Endothelial interactions of hairy cells: the importance of alpha 4 beta 1 in the unusual tissue distribution of the disorder. Blood. 1996;88:3945-3952.
132. Csanaky G, Matutes E, Vass JA et al. Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leucemia. 1997;11:408-415
133. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991;78:206-209.
134. El Weshi A, Ribrag V, Girinski T, El Hajj M, Dhermain F, Bayle C. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol. 1998;103:1212-1213.
135. Matutes E. Catovski D. Clinical and laboratory features of splenic lymphoma with villous lymphocytes. In Armitage JO, Newland A, Keatty A, et al, eds. Cambridge Medical Reviews Haematology Oncology. Vol.4 Cambridge, United Kingdom: Cambridge University Press; 1993:149-150.
136. Iannitto E, Cirrincione S, Pagliaro M, et al. Pentostatin in the treatment of splenic lymphoma with villous lymphocytes. A phase II study. Preliminary results [abstract]. Blood. 2001;98:558.
137. Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorode-oxyadenosine (2-CdA) [letter]. Br J Haematol. 1998;100:609.
138. Lefrere F, Hermine O, Francois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2000;40:113-117.
139. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol. 1997;99:158-161.
140. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia. 2000;14:573-575.
141. Tchiknavorian X, Otto J, Pivot X, Arnaud MC, Schneider M, Thyss A. Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin. Hematol Cell Ther. 1999;41:233-234.
142. Thomas DA, O'Brien S, Cortes J, et al. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal lymphoma (MZL) with single agent rituximab [abstract]. Blood. 2001;98:563.
143. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201.
144. Hermine O, Lefrere F, Bronowicki J-P, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89-94.